Caloric and nutrient restriction to augment chemotherapy efficacy for acute lymphoblastic leukemia: the IDEAL trial

Abstract

Being overweight or obese (OW/OB) during B-cell acute lymphoblastic leukemia (B-ALL) induction is associated with chemoresistance as quantified by minimal residual disease (MRD). We hypothesized that caloric and nutrient restriction from diet/exercise could lessen gains in fat mass (FM) and reduce postinduction MRD. The Improving Diet and Exercise in ALL (IDEAL) trial enrolled patients 10 to 21 years old, newly diagnosed with B-ALL (n = 40), in comparison with a recent historical control (n = 80). Designed to achieve caloric deficits ≥20% during induction, reduce fat intake/glycemic load, and increase activity, IDEAL's end points were FM gain (primary), MRD ≥0.01%, and adherence/feasibility. Integrated biology explored biomarkers of OW/OB physiology. IDEAL intervention did not significantly reduce median FM change from baseline overall (+5.1% [interquartile range [IQR], 15.8] vs +10.7% [IQR, 16.0]; P = .13), but stratified analysis showed benefit in those OW/OB (+1.5% [IQR, 6.6] vs +9.7% [IQR, 11.1]; P = .02). After accounting for prognostic factors, IDEAL intervention significantly reduced MRD risk (odds ratio, 0.30; 95% confidence interval, 0.09-0.92; P = .02). The trial exceeded its adherence (≥75% of overall diet) and feasibility (≥80% completed visits) thresholds. Integrated biology found the IDEAL intervention increased circulating adiponectin and reduced insulin resistance. The IDEAL intervention was feasible, decreased fat gain in those OW/OB, and reduced MRD. This is the first study in any hematologic malignancy to demonstrate potential benefit from caloric restriction via diet/exercise to augment chemotherapy efficacy and improve disease response. A prospective, randomized trial is warranted for validation. These trials were registered at www.clinicaltrials.gov as #NCT02708108 (IDEAL trial) and #NCT01317940 (historical control).

Conflict of interest statement

Conflict-of-interest disclosure: E.O. served on an advisory board for Servier Pharmaceuticals outside of the scope of this work. The remaining authors declare no competing interests.

© 2021 by The American Society of Hematology.

Figures

Graphical abstract

Figure 1.

Change in FM and LM during induction. Compared with historical controls, change in FM from baseline (A) was decreased in those OW/OB (BMI ≥85%) at diagnosis in the IDEAL cohort but not in those lean (BMI <85%). Change in LM from baseline (B) was not significantly different for either group. *Significant at 2-sided P < .05.

Figure 2.

MRD at EOI. Prevalence of MRD ≥0.01% at EOI in the IDEAL cohort as compared with historical controls and stratified by starting BMI. In the IDEAL trial, 24 of 38 (63%) evaluable for MRD at EOI were OW/OB as compared with 35 of 80 (44%) in the historical control.

Figure 3.

A/L ratio at EOI. A/L ratio is a sensitive measure for insulin sensitivity and healthy adipocytes. A/L ratio at EOI was higher for both lean and OW/OB patients treated in the IDEAL trial as compared with the historical control. **Significant at 2-sided P < .01.